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We have used accurate mass precursor ion data generated on a hybrid linear-ion trap-Fourier
transform ion cyclotron resonance mass spectrometer to augment tandem mass spectrometry
(MS/MS) data generated on two different instrument types. Results from these experiments have
allowed us for the first time to identify a naturally processed peptide presented by a class I human
leukocyte antigen allele (HLA-A*0201) that was isolated from B cells infected by live vaccinia, the
viral agent of the smallpox vaccine. The accurate mass data, in conjunction with MS/MS data, was
able to identify the sequence IVIEAIHTV (aa 187-195) from the protein thymidylate kinase of
vaccinia, distinguishing it from a similar sequence IVLEAIAEH: a “self-peptide” from the human
protein phospholipase C3. Accurate mass data for the doubly charged species from the naturally
processed and presented peptide was 497.8006, which was within 0.8 ppm of the calculated m/z of
497.8002, while being 37.3 ppm from the calculated m/z (497.7820) of the second-ranked peptide
sequence IVLEAIAEH. Accurate mass data ranged from less than 0.1 to 1.2 ppm for other peptides
identified in this sample. A BLAST search shows this sequence, IVIEAIHTV, is conserved in the
same protein of a number of other orthopoxviruses, including the variola (smallpox) virus.
Additionally, accurate mass data were able to uncover a false positive search result that was not
distinguished by scoring of the match to the MS/MS data. (J Am Soc Mass Spectrom 2005, 16,
1812–1817) © 2005 American Society for Mass SpectrometryAdvances in mass spectrometry instrumentationand associated analytical methods have led tounprecedented growth in the application of
mass spectrometry to research in the life sciences. The
development of electrospray ionization [1], advances in
miniaturized chromatography [2, 3], tandem mass spec-
trometry (MS/MS) of peptides [4], and multidimen-
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have successively enabled other researchers in the ap-
plication of mass spectrometry to their respective areas
of research. As an example, we have employed the use
of multidimensional LC together with automated acqui-
sition of MS/MS data for the identification of self-
peptides and peptides originating from measles virus
proteins that were displayed by the human leukocyte
antigen (HLA) class II system from cultured B cells
infected with measles virus [7–9].
Recently, the development and commercialization of
hybrid mass spectrometers incorporating Fourier trans-
form ion cyclotron resonance (FTICR) analyzers, with
high resolving power (RP) and high mass accuracy offer
additional opportunities to enhance the usefulness of
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result, the effectiveness of combining accurate mass
data from the precursor ion with MS/MS data has been
reported [12, 13].
This report describes an example where the high mass
accuracy of a hybrid two dimensional (2D)-ion trap-
FTICR-mass spectrometry (MS) instrument combined
with MS/MS data enables confident sequence assignment
of a naturally processed and presented class I peptide
originating from vaccinia, the viral agent used in the
smallpox vaccine, and distinguishing it from a similar
sequence from the human protein phospholipase C3.
T-helper cells play an important role in orchestrating
the effector function of cytotoxic T lymphocytes (CTLs)
in immunity against orthopoxvirus infection. Only a
few vaccinia virus class I peptides and HLA-A*0201-
restricted CD8 T cells are described in the literature
[14-16]; however, no naturally processed and presented
vaccinia virus T-cell epitopes have been identified. One
major obstacle is the size of the virus. Vaccinia is a large,
double-stranded virus, which replicates in the nucleus
of infected cells, with an200-kilobase-pair (kbp) DNA
genome, encoding more than 230 open reading frames
and expressing more than 200 proteins [17, 18]. In
addition, information about immunodominant or-
thopoxvirus antigens and epitope specificities of virus-
specific CTL responses is still lacking [14]. Therefore,
the role of specific peptides presented in the context of
HLA molecules to T cells can be considered as one of
the most important fundamental questions for under-
standing immune responses to vaccinia and other or-
thopoxviruses. In this study, we report a new naturally
processed and HLA-A*0201-presented peptide epitope
derived from vaccinia virus, which is encoded by the
vaccinia virus gene thymidylate kinase (TmpK) and
is highly conserved in vaccinia, variola, and other
orthopoxviruses.
Experimental
Vaccinia Infection of B Cells
The New York City Board of Health vaccine-strain of
vaccinia virus (Dryvax™) was cultured in HeLa cells in
Dulbecco’s modified Eagle’s medium, supplemented
with 5% fetal calf serum (virus stocks of 6.3  108
plaque-forming units [pfu]/mL). An established
Epstein-Barr virus-transformed human HLA-A*0201
homozygous cell line, Priess (cell ID no. 11,277; Euro-
pean Collection of Cell Cultures, Salisburg, Wiltshire,
UK) was used for this study. Cells were infected with
live vaccinia virus at a multiplicity of infection of 0.1
pfu/cell for 2 h and maintained for 24 h at 37 °C. The
uninfected and vaccinia-infected cells were used for
obtaining cell lysates for purification of HLA-A2 mole-
cules. Equal-sized batches of uninfected and vaccinia-
infected cells were prepared, washed in phosphate-
buffered saline, pelleted, and stored at 80 °C for
isolation of HLA-A*0201 molecules and HLA-A*0201-bound peptides. Infection of cells with vaccinia was
confirmed by flow cytometry using a polyclonal anti-
vaccinia antibody specific for vaccinia proteins (Fitz-
gerald Industries International, Inc., Concord, MA),
followed by a fluorescein isothiocyanate-conjugated
secondary antibody (data not shown).
Production of HLA-A2 Monoclonal Antibodies
and Construction of Immunoaffinity Column
The PA2.1 hybridoma (ATCC, Manassas, VA) was the
source of HLA-A2-reactive monoclonal antibody
(mAb). PA2.1 hybridoma cells (1  105/mL) were
cultured for 2-3 days in modified Dulbecco’s medium.
The hybridoma supernatants were collected, and im-
munoglobulin G (IgG) antibodies were purified using a
protein G-Sepharose fast flow column (Pharmacia, Pea-
pack, NJ). Immunoaffinity columns were constructed
using protein A-Sepharose (Sigma-Aldrich Corp., St.
Louis, MO), covalently coupled to the purified HLA-
A2-specific mAb (PA2.1, IgG1). For coupling, 20 mM of
dimethyl pimelimidate dihydrochloride (DMP) was
used. Briefly, 7.5 mL of protein A-Sepharose was
washed in 20 mL of 100-mM borate buffer, pH 8.2.
Anti-HLA-A2 mAb (1.66 mg/mL) was diluted (15 mg
to 30 mL) with 100 mM of borate buffer, pH 8.2, and
mixed with Sepharose for 30 min. After incubation, the
Sepharose beads were spun at 1500 rpm and protein
concentration of the supernatant was measured at 280
nm. Sepharose was poured into the column with sin-
tered glass and was washed with 100 mM of borate
buffer, pH 8.2, and 200 mM of triethanolamine, pH 8.2.
Protein A-Sepharose then was coupled with fresh 20
mM of DMP in 200 mM of triethanolamine, pH 8.2, for
45 min by rocking and washing with 20 mL of 20-mM
ethanolamine to block residues. Finally, Sepharose
beads were washed with 100 mM of borate buffer, pH
8.2, and equilibrated with 0.1% Nonidet-40 and 10 mM
of Tris, pH 8.0.
Isolation of HLA-A*0201-Associated Peptides
Uninfected and vaccinia-infected B cells were solubi-
lized in 20 mM of Tris, pH 8.0, 150 mM of NaCl, 1%
CHAPS (N,N-Dimethyl-N-(3-sulfopropyl)-3-[[(3,5,
7,12)-3,7,12-trihydroxy-24-oxocholan-24-yl]amino]-
1-propanaminium inner salt; 3-[(3-cholamidopropyl)-
dimethylammonio]-1-propanesulfonate) 2 mM of phe-
nylmethylsulfonyl fluoride, 100 M of iodoacetamide,
aprotinin (5 g/mL), leupeptin (10 g/mL), pepstatin
A (10 g/mL), ethylenediaminetetraacetic acid (3 ng/
mL), and 0.2% sodium azide. After sample centrifuga-
tion at 100,000g for 1 h, supernatants were passed
through an immunoaffinity column with HLA-A2.1-
specific mAb (PA2.1) and protein A-Sepharose.
HLA-A2 molecules were eluted from the column with
50 mM of diethylamine, pH 11.5, 0.4% n-octyl-
glucoside, 150 mM of NaCl, and 0.02% NaN3. Eluates
were neutralized with 1M Tris, pH 6.8, and concen-
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Amicon Corp., Danvers, MA). Acetic acid (14%) was
used to dissociate any bound peptides from HLA-A2
molecules. The peptides were stored at 80 °C for later
analysis by mass spectrometry.
Desalting Peptides
Before 2D-LC, HLA class I peptides were desalted on a
1 mm i.d. (inner diameter) by 10 mm long reversed-
phase cartridge (PeptideTrap; Michrom BioResources,
Inc., Auburn, CA), vacuum-concentrated to 10 L,
and dilutedwith 15L ofwater/acetonitrile/n-propanol/
formic acid (98.5/1/0.5/0.2 by volume) also containing
0.0005% heptafluorobutyric acid and 0.5 mM of ammo-
nium acetate.
Strong Cation Exchange Fractionation
Strong cation exchange (SCX) separations were per-
formed using a 0.5-mm i.d. by 150 mm long Polysulfo-
ethyl A column (Michrom BioResources, Inc.) at a flow
rate of 25 L/min. A gradient of 5 mM of KH2PO4 (pH
3.1)/10% acetonitrile into 500 mM of KCl (in the same
phosphate/acetonitrile buffer) was used to fractionate
peptides at 1-min intervals. The mobile phase gradient
started at 0% B with linear gradients to 20% B at 20 min
and 80% B at 30 min, followed by a 5-min hold at 80%
B, 5 min to return to 0% B, and a 15-min re-equilibration
period (50 min total method). A 1-m length of 100 m
i.d. fused silica (8 L volume, 0.33 min delay at 25
L/min) was used to collect fractions via a Gilson FC
203B fraction collector.
Quadrupole Time-of-Flight LC-MS/MS Analyses
Initial automated LC-MS/MS analyses were done on a
CapLC interfaced with a Q-ToF II (Waters Corp., Bed-
ford, MA), using a 24-cm by 75 m i.d. column packed
in-house with Targa C18 (Higgins Analytical, Mountain
View, CA). The autosampler loaded 10-L aliquots of
SCX fractions onto a 0.25-L precolumn (Optimize
Technologies, Oregon City, OR), custom-packed with
Michrom Magic C8, 5 m, 300 Å (Michrom BioRe-
sources, Inc.), which was inserted into a Cheminert
10-port switching valve (Valco Instruments Co., Inc.,
Houston, TX). Mobile phase A was water/acetonitrile/
n-propanol/formic acid (98/1/1/0.2 by volume) and
mobile phase B was acetonitrile/n-propanol/water/
formic acid (80/10/10/0.2 by volume). A gradient from
3-50% B over 60 min was used at an approximate
column flow of 0.2 L/min. Pump C on the CapLC was
used to transfer samples from the autosampler to the
precolumn, using a 10-L/min flow of water/acetoni-
trile/n-propanol/formic acid (98/1/1/0.2 by volume)
that additionally contained 0.5 mM of ammonium ace-
tate. A 10-min transfer period (100 L) was used to
transfer the sample and wash potassium salts from the
peptides before switching the precolumn in line with
the LC column and starting the reversed-phase gradient.Automated MS/MS measurements were performed
on the three most intense doubly charged ions, using
charge and m/z-dependent selection of collision ener-
gies. MS/MS spectra were searched against the NCBI nr
(National Center for Biotechnology Information, non-
redundant) database using MASCOT software, without
enzyme constraints, using a precursor mass window of
0.3 mass units and a fragment ion mass window of 0.2
mass units [19].
Hybrid Linear Ion Trap Quadrupole-FTICR
LC-MS/MS Analyses
Accurate mass LC-FTICR-MS/MS measurements were
performed on a ThermoFinnigan LTQ-FT (ThermoElec-
tron, Bremen, Germany). A Michrom Paradigm LC
(Michrom BioResources) plumbed with a 75-m i.d.
by 5-cm length Integrafrit column packed with
ProteoPep II (New Objective, Woburn, MA) was used
for the LC separation. The sample was loaded on a
0.3-mm i.d. by 1-mm long precolumn packed with
PepMap stationary phase (Dionex, Sunnyvale, CA).
The LTQ-FT was operated in a data-dependent mode
similar to that described in Olsen et al. [13], where a
medium RP (25,000 full width at half maximum FWHM
at m/z 400) scan from m/z 375-1600 was acquired in the
FTICR analyzer, followed by a high RP (RP  50,000
FWHM at m/z 400) FTICR SIM scan over a 10 m/z
window, with linear-ion trap collision induced dissoci-
ation (CID) experiments on the top three most abundant
ions [13]. The ion population target value for the FTICR
full scan and SIM scan were set at 3  106 and 1  105,
respectively. For MS/MS experiments the ion trap
target population was set to 1  105; collision energy
was set to 35%.
Results and Discussion
Among the highly polymorphic human HLA class I
molecules we chose the HLA-A*0201 allele, part of the
HLA-A2 supertype, to search for CD8 vaccinia virus
T-cell epitopes because the HLA-A2 supertype is ex-
tremely prevalent in the general population (50%)
[20], its crystal structure has been solved [21], and its
ligand specificity has been examined in detail [4, 22, 23].
We infected a Class I HLA-A*0201 homozygous cell line
with live vaccinia virus, and then searched for naturally
processed and presented vaccinia virus-derived peptides.
Initial Mascot search results of MS/MS spectra gen-
erated by the Q-Tof II identified self-peptides and
peptides unique to bovine albumin, the latter attributed
to the fetal calf serum used to culture the B cells from
which peptides were harvested. In addition, an MS/MS
spectrum from SCX fraction 21 was tentatively identi-
fied as IVIEAIHTV (aa 187-195) from the protein TmpK
of vaccinia virus, the immunogenic agent in the small-
pox vaccine. TmpK catalyzes a critical step in the
biosynthesis of (deoxy)thymidine triphosphate and is
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shows this sequence is conserved across a number of
other poxvirus families.
Figure 1a shows the spectrum obtained on the Q-ToF
II. The MS/MS search results were not conclusive:
Figure 1. MS/MS and FTICR-MS data for a class I peptide
identified as IVIEAIHTV from TmpK of vaccinia. (a) Q-ToF II
MS/MS spectrum (collision energy  18 V. (b) MS/MS spec-
trum from a linear-ion trap-FTICR hybrid instrument (LTQ-FT).
MS/MS ions marked with an asterisk (*) denote fragmentation
products that distinguish the sequence IVIEAIHTV from
IVLEAIEAH. All other labeled fragment ions support both se-
quences. The inset of panel (b) shows the FTICR accurate mass
spectrum of the doubly charged precursor ion that conclusively
identifies the correct sequence as IVIEAIHTV.
Table 1. List of top 10 most closely matched peptide sequences
Sequence Chemical formula MOWSE sco
IVIEAIHTV C45H79N11O13 46.4
IVLEAIAEH C45H75N11O14 46.4
LVLESPSHI C45H75N11O14 46.4
IVIESPIHS C45H75N11O14 46.4
IVLELACYA C46H75N9O13S1 46.4
LVLEVNNPP C45H75N11O14 42.1
LVLELLTHG C46H79N11O13 42.1
LVIDVELPP C47H79N9O14 36.5
LVLDVEIHG C45H75N11O14 36.5
LVLTLVLSH C47H83N11O12 34.2Spectrum shown in Figure 1a. The right column lists the deviation in mass o
obtained on a hybrid FTICR-MS instrument. Candidate sequences 3–10 candespite the presence of a strong y-ion series, the
MOWSE [19] score for the top match was 46, with
thresholds of 56 for similarity and 68 for identity. In
addition, the top five matches all had the same score. In
particular, the sequence IVLEAIAEH from phospho-
lipase C3 gave the same score and also equally ac-
counted for the major fragment ions observed in the
spectrum. Only three minor fragment ions, marked
with asterisks (*) in Figure 1, serve to differentiate the
sequence of IVIEAIHTV from IVLEAIAEH.
Table 1 lists the top 10 sequence candidates, their
chemical formula, MOWSE score, and m/z of their
doubly charged ion. Candidate sequences 3-10 can be
Figure 2. MS/MS spectra from (a) a naturally processed peptide
isolated from vaccinia-infected B cells and (b) synthesized peptide
with the sequence IVIEAIHTV, a sequence from TmpK that is
conserved in a number of poxviruses (listed in Table 2). Each
spectrum was acquired with a collision energy of 18 V.
a MASCOT search of an MS/MS spectrum from a Q-Tof II
Mr [M  2H
]2 m/z (ppm)
993.58588 497.80022 0.8
993.54950 497.78203 37.3
993.54950 497.78203 37.3
993.54950 497.78203 37.3
993.52051 497.76753 66.4
993.54950 497.78203 37.3
993.58588 497.80022 0.8
993.57465 497.79460 12.1
993.54950 497.78203 37.3
993.62227 497.81841 35.8from
ref each of the sequences relative to an experimental result of 497.8006
be more readily distinguished by the MS/MS data.
. . .
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higher y ions are common to the first seven sequences.
The first two candidate sequences differ in doubly
charged mass by 0.018 mass units or 36 ppm (36 ppm).
The remainder of SCX fraction 21 was analyzed on a
ThermoFinnigan LTQ-FT. Results from this analysis on
the LTQ-FT are shown in Figure 1b, where, first, the
MS/MS spectrum from the LTQ-FT corroborates the
MS/MS spectrum from the Q-Tof II shown in Figure 1a.
Second, the inset of Figure 1b shows the precursor SIM
scan from the FTICR analyzer that measured the doubly
chargedm/z as 497.8006. The column on the right side of
Table 1 lists the deviations of this measured m/z from
the theoretical m/z values for each of the top 10 candi-
date sequences. The measured m/z is within 0.8 ppm of
the calculated mass of IVIEAIHTV from vaccinia but is
37.3 ppm from the alternate sequence IVLEAIAEH from
phospholipase C3. The seventh candidate sequence
from Table 1, LVLELLTHG, also has the same chemical
formula as IVIEAIHTV; however, the y2, y3, and y4 ions
from the tandem mass spectra serve to distinguish
between the two sequences.
Because peptides presented by class I and II HLA
molecules are not C-terminally constrained to Arg, Lys,
or the protein C-terminus, many more candidate se-
quences will pass initial precursor ion mass filtering, to
be subsequently scored on the basis of matching frag-
ment ions. Although accurate mass precursor ion data
alone can not definitively identify these peptides, it
greatly decreases the number of candidate sequences to
be matched against the fragment ion data. When this
MS/MS spectrum is searched using a precursor toler-
ance of 20 ppm, the only match is IVIEAIHTV from
vaccinia. It is noted that methylation of acidic residues
followed by reanalysis also would serve to differentiate
these two sequences at the cost of the additional deriv-
itization procedure and its potential for further sample
Table 2. Conservation of the naturally processed and presented
poxviruses causing infection in humans
Orthopox
GenBank
accession no.
Vaccinia virus
Modified vaccinia Ankara (MVA) U94848 M
Copenhagen M35027 A
Tian Tan AF095689 T
Western reserve (WR) V
Variola major
Bangladesh—1975 ML22579 J2
India—1967 MX69198 J2
Variola minor
Garcia—1966 MY16780 K
Cowpox virus
Brighton Red MAF482758 C
Monkeypox
Zaire-96-1-16 MAF380138 A
Camelpox
Camelpox M-96 (Kazakhstan) MAF438165 156596loss.To frame this accurate mass result within the context
of other identified peptides, we calculated the accurate
mass deviations for six additional peptides. Five of six
results ranged from less than 0.1 to 1.2 ppm mass error,
consistent with results we have observed for tryptic
peptides (data not shown). The sixth peptide’s precur-
sor mass was 15.7 ppm from the proposed sequence.
The MOWSE score for this peptide was 40 (40 for
homology, 50 for identity). Inspection of the match
results from this peptide showed that six of the nine
fragment ions with greater than 50% relative abundance
were not matched, strongly suggesting the proposed
sequence was incorrect. The MOWSE score did not
differentiate this false positive result from other results
of similar MOWSE score, while the mass error of the
precursor ion relative to the proposed sequence clearly
differentiated this incorrect search result from the other
peptides in this set.
We also had the peptide IVIEAIHTV synthesized,
which was then analyzed by LC-MS/MS on our Q-Tof-
II. Figure 2 shows the original MS/MS spectrum from
the naturally processed peptide (upper trace) compared
with the MS/MS spectrum from the synthesized pep-
tide, showing the close agreement in fragmentation
patterns and again confirming our identification.
When we looked at other orthopoxviruses, we ob-
served that this epitope, IVIEAIHTV, is highly con-
served in vaccinia, variola, cowpox, monkeypox, and
camelpox viruses (Table 2). This suggests that if human
CTL will recognize this epitope, they will most likely
recognize variola virus-infected cells as well. Because
this epitope is endogenously processed and presented
on HLA-A2 molecules of infected cells, one can hypoth-
esize that CD8 T cells raised by immunization and
restimulation with this peptide will most likely recog-
nize cells infected with vaccinia virus. Thus, it may be
I HLA-A*0201 vaccinia-derived peptide IVIEAIHTV among
name Protein ID Protein name
61R AAB96539.1 thymidylate kinase (TmpK)
AAA48180.1 CDS A48R, putative
AAF34060.1 AAF34060.1 protein
R174 AAO89453.1 TmpK
AAA60903.1 homolog of vaccinia virus
CDS A48R (TmpK)
CAA49101.1 NA
CAB54761.1 K2R protein
86 CDS AAM13626.1 CPXV186 protein
AAL40617.1 similar to Copenhagen A48R
1572 79 CDS AAL73876.1 TmpKclass
Gene
VA1
48R
A59R
ACW
R
R
2R
PXV1
49Rpossible to develop a new peptide-based smallpox
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and presented vaccinia peptides.
Conclusion
We have used accurate mass measurement of the pre-
cursor ion in conjunction with MS/MS to identify a
novel HLA class I peptide from a vaccinia protein that
is presented after infection of B cells with live vaccinia
virus. The MS/MS data, in conjunction with accurate
mass data for the precursor ion, identifies the peptide as
IVIEAIHTV from the TmpK protein of vaccinia virus.
The combination of 2D-LC for peptide separation, with
MS/MS and precursor ion accurate mass data, is a
powerful tool for identifying naturally processed pep-
tides presented by the HLA pathway. In the examples
reported here for naturally processed peptides lacking
the C-terminal amino acid restraints of a tryptic or
Lys-C generated peptide, accurate mass has been used
to both augment fragmentation data and as a means of
discovering false positives from database search results.
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